It's interesting that it's priced at $1850/month wholesale.
If TFA is to be believed, schizophrenia is quite common so the market is vast and the usual excuses of "price has to be high to recoup R&D because of low demand" doesn't seem like it would apply.
A mere 1M worldwide prescriptions (there's 6x that amount of people with schizophrenia in America alone) means 22 billions per year raw revenue.
If they get 1M patients, they make $22B, so "the usual excuses of "price has to be high to recoup R&D because of low demand" doesn't seem like it would apply."?
They are not all going to get it right away, there are competitive drugs, it will first be used for patients who can’t tolerate current drugs. (Actually quite a few of them)
A lot of people with schizophrenia and related conditions are untreated. I know someone right now who is in her 40s and about to lose her housing who almost certainly has schizophrenia (sure has the thought disorder, if we want to pick her up to do something we might have to attempt it several times to pick her up, has grandiose delusions, no sign of hallucinations though, hasn’t really worked in 10 years) although she is undiagnosed and doesn’t believe there is anything wrong about her.
If you look at the homeless population I think you see a lot of schizophrenia and PSTD.
If TFA is to be believed, schizophrenia is quite common so the market is vast and the usual excuses of "price has to be high to recoup R&D because of low demand" doesn't seem like it would apply.
A mere 1M worldwide prescriptions (there's 6x that amount of people with schizophrenia in America alone) means 22 billions per year raw revenue.